Increased levels of copeptin before clinical diagnosis of preelcampsia

Hypertension

Volumn 64, Issue 6, 2014, Pages 1362-1367

  Yeung, Edwina H ^a   Liu, Aiyi ^a   Mills, James L ^a   Zhang, Cuilin ^a   Männistö, Tuija ^a   Lu, Zhaohui ^b   Tsai, Michael Y ^c   Mendola, Pauline ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b Glotech Inc   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Copeptin; Diabetes; Gestational; Human; Hypertension; Preeclampsia; Pregnancy induced

Indexed keywords

COPEPTIN; BIOLOGICAL MARKER; GLYCOPEPTIDE; PROTEIN PRECURSOR;

ADULT; ARTICLE; BODY MASS; CHROMOSOME ABERRATION; DIASTOLIC BLOOD PRESSURE; FEMALE; GESTATIONAL AGE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MARRIAGE; MATERNAL AGE; MATERNAL HYPERTENSION; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; PROTEINURIA; RANK SUM TEST; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; MULTICENTER STUDY; NEWBORN; PATHOPHYSIOLOGY; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RISK; RISK FACTOR; YOUNG ADULT;

BIOLOGICAL MARKERS; BLOOD PRESSURE; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLYCOPEPTIDES; HUMANS; INFANT, NEWBORN; ODDS RATIO; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PROTEIN PRECURSORS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; YOUNG ADULT;

EID: 84922480094     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03762     Document Type: Article

References (39)

1. Steegers EA, Von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631-644.
2. Duley L, Meher S, Abalos E. Management of pre-eclampsia. BMJ. 2006;332:463-468.
3. Naljayan MV, Karumanchi SA. New developments in the pathogenesis of preeclampsia. Adv Chronic Kidney Dis. 2013;20:265-270.
4. Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, Adachi T, Tanaka T, Kuwaki T, Mori T, Takeo S, Okamura H, Tsujimoto G. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci U S A. 2006;103:7807-7812.
5. Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92:1813-1864.
6. Schrier RW. Systemic arterial vasodilation, vasopressin, and vasopressinase in pregnancy. J Am Soc Nephrol. 2010;21:570-572.
7. Tkachenko O, Shchekochikhin D, Schrier RW. Hormones and hemodynamics in pregnancy. Int J Endocrinol Metab. 2014;12:e14098.
8. Durr JA, Stamoutsos B, Lindheimer MD. Osmoregulation during pregnancy in the rat. Evidence for resetting of the threshold for vasopressin secretion during gestation. J Clin Invest. 1981;68:337-346.
9. Barron WM, Dürr J, Stamoutsos BA, Lindheimer MD. Osmoregulation and vasopressin secretion during pregnancy in Brattleboro rats. Am J Physiol. 1985;248(1 Pt 2):R29-R37.
10. Grazzini E, Breton C, Derick S, Andres M, Raufaste D, Rickwaert F, Boccara G, Colson P, Guérineau NC, Serradeil-Le Gal C, Guillon G. Vasopressin receptors in human adrenal medulla and pheochromocytoma. J Clin Endocrinol Metab. 1999;84:2195-2203.
11. Krege JH, Katz VL. A proposed relationship between vasopressinase altered vasopressin and preeclampsia. Med Hypotheses. 1990;31:283-287.
12. Gordge MP, Williams DJ, Huggett NJ, Payne NN, Neild GH. Loss of biological activity of arginine vasopressin during its degradation by vasopressinase from pregnancy serum. Clin Endocrinol (Oxf). 1995;42:51-58.
13. Baumann G, Dingman JF. Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest. 1976;57:1109-1116.
14. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112-119.
15. Gordge MP, Robson SC, Williams DJ, Payne NN, Neild GH. Serum Vasopressinase and Platelet Responses to Arginine Vasopressin in Normal Pregnancy, Pregnancy-induced Hypertension and Pre-eclampsia. Platelets. 1994;5:90-95.
16. Enhörning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, Melander O. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010;121:2102-2108.
17. Levine RJ, Esterlitz JR, Raymond EG, et al. Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods. Control Clin Trials. 1996;17:442-469.
18. Levine RJ, Hauth JC, Curet LB, Sibai BM, Catalano PM, Morris CD, Der Simonian R, Esterlitz JR, Raymond EG, Bild DE, Clemens JD, Cutler JA. Trial of calcium to prevent preeclampsia. N Engl J Med. 1997;337:69-76.
19. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005.
20. Joffe GM, Esterlitz JR, Levine RJ, Clemens JD, Ewell MG, Sibai BM, Catalano PM. The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol. 1998;179:1032-1037.
21. Braunstein G. Endocrine changes in pregnancy. In: Melmed S, Polonsky KS, Larsen RP, Kronenberg HM, eds. Williams Textbook of Endocrinology. 12th ed. Philadelphia: Saunders Elsevier; 2011:819-832.
22. Davison JM, Sheills EA, Barron WM, Robinson AG, Lindheimer MD. Changes in the metabolic clearance of vasopressin and in plasma vasopressinase throughout human pregnancy. J Clin Invest. 1989;83:1313-1318.
23. Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol. 2013;9:223-239.
24. Okada H, Suzuki H, Kanno Y, Yamamura Y, Saruta T. Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats. Clin Sci (Lond). 1994;86:399-404.
25. Okada H, Suzuki H, Kanno Y, Saruta T. Evidence for the involvement of vasopressin in the pathophysiology of adriamycin-induced nephropathy in rats. Nephron. 1996;72:667-672.
26. Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, Lonergan M, Ruel N, Bouby N, Bankir L. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant. 2003;18:497-506.
27. Risberg A, Olsson K, Lyrenas S, Sjöquist M. Plasma vasopressin, oxytocin, estradiol, and progesterone related to water and sodium excretion in normal pregnancy and gestational hypertension. Acta Obstet Gynecol Scand. 2009;88:639-646.
28. Eguchi K, Oguni N, Sawai T, Yonezawa M. Comparison of plasma concentrations of arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) in normal and preeclamptic pregnancies. J Perinat Med. 1996;24:437-443.
29. Foda AA, Abdel Aal IA. Maternal and neonatal copeptin levels at cesarean section and vaginal delivery. Eur J Obstet Gynecol Reprod Biol. 2012;165:215-218.
30. Wellmann S, Benzing J, Fleischlin S, Morgenthaler N, Fouzas S, Buhrer CA, Szinnai G, Burkhardt T, Lapaire O. Cardiovascular biomarkers in preeclampsia at triage [published online ahead of print May 17, 2004]. Fetal Diagn Ther. doi:10.1159/000361016. http://www.karger.com/Article/FullText/361016. Accessed June 16, 2014.
31. Zulfkaroglu E, Islimye M, Tonguc EA, Payasli A, Isman F, Var T, Danisman N. Circulating levels of copeptin, a novel biomarker in preeclampsia. J Obstet Gynaecol Res. 2011;37:1198-1202.
32. Santillan MK, Santillan DA, Scroggins SM, Min J Y, Sandgren JA, Pearson NA, Leslie KK, Hunter SK, Zamba GK, Gibson-Corley KN, Grobe JL. Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model [published online ahead of print July 7, 2014]. Hypertension. doi: 10.1161/HYPERTENSIONAHA.114.03848. http://hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03848. Accessed July 21, 2014.
33. Fujiwara Y, Hiroyama M, Sanbe A, Aoyagi T, Birumachi J, Yamauchi J, Tsujimoto G, Tanoue A. Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. J Physiol. 2007;584(Pt 1):235-244.
34. Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort RT, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ. Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia. 2012;55:1963-1970.
35. Oncul M, Tuten A, Kucur M, Imamoglu M, Ekmekci OB, Acikgoz AS, Madazli R. Copeptin concentrations are not elevated in gestational diabetes mellitus. Arch Gynecol Obstet. 2013;288:1045-1049.
36. Boucoiran I, Thissier-Levy S, Wu Y, Wei SQ, Luo ZC, Delvin E, Fraser WD, Audibert F; MIROS Study Group. Risks for preeclampsia and small for gestational age: predictive values of placental growth factor, soluble fms-like tyrosine kinase-1, and inhibin A in singleton and multiple-gestation pregnancies. Am J Perinatol. 2013;30:607-612.
37. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, Van Der Post JA, Von Dadelszen P, Mol BW, Pajkrt E; EBM CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and metaanalysis. BJOG. 2012;119:778-787.
38. Myatt L, Clifton RG, Roberts JM, et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol. 2012;119:1234-1242.
39. Myers JE, Kenny LC, McCowan LM, Chan EH, Dekker GA, Poston L, Simpson NA, North RA; SCOPE Consortium. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG. 2013;120:1215-1223.